NOTICE OF INTENT TO AWARD A SOLE SOURCE COMMERCIAL SIMPLIFIED ACQUISITION PROCEDURES (SAP) CONTRACT FOR DEVELOPMENT OF A HUMAN NEURAL NETWORK FORMATION NEW APPROACH METHOD FOR THE EVALUATION OF POTENTIAL DEVELOPMENTAL NEUROTOXICITY

AI Summary

The FDA intends to award a sole source contract to Cyprotex US, LLC for developing a human neural network formation method to evaluate potential developmental neurotoxicity. This acquisition follows simplified acquisition procedures under FAR Part 12. Responses must be submitted by July 10, 2026, to be considered.

Contract details

Solicitation No.: HFP-2026-134390
Notice Type: Special Notice
Posted Date: July 5, 2026
Response Deadline: July 10, 2026
NAICS Code: 541690 AI guide
PSC / Class Code: B599
Issuing Office: FDA OFFICE OF ACQ GRANT SVCS
Sub-Agency: FOOD AND DRUG ADMINISTRATION
Agency: DEPARTMENT OF HEALTH AND HUMAN SERVICES
Primary Contact: Haroon Gulzar
City: ROCKVILLE
State: MD
ZIP Code: 20857
AI Product/Service: service

Description

The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price contract to Cyprotex US, LLC, 200 Staples Drive, Framingham, MA 01702, USA, incorporated for the purchase of Development of a Human Neural Network Formation New Approach Method for the Evaluation of Potential Developmental Neurotoxicity, in accordance with the authority under FAR Part 6.302-1. Only one responsible source and no other supplies or services will satisfy agency requirements.

Cyprotex US, LLC is qualified for DT/OCT/OLOAS/HFP unique requirement because they are the only vendor that offers a neural network formation NAM which utilizes microelectrode array (MEA) technology that can be appropriately adapted for the agency specific needs.

This acquisition is being conducted using simplified acquisition procedures in accordance with FAR RFO Part 12 for the acquisition of commercial products and commercial services.

The North American Industry Classification System (NAICS) code for the proposed acquisition is 541690 - Other Scientific and Technical Consulting Services.

Deliverables

Raw experimental data, noting any deviations from standard procedure - Electronic file (.csv or .RData preferred) - Estimated Delivery Date - 01/31/27

Responses

Responses to this notice should be sent to Haroon Gulzar at haroon.gulzar@fda.hhs.gov no later than 5:00 pm (ET) on July 10, 2026. This notice is not a request for competitive quotes. Any other firms desiring consideration must fully identify their interest and capability of meeting the requirements by submitting a capability statement. Any response shall undergo review to determine if it can meet the requirements. A determination by the Government not to compete this proposed requirement based upon a response to this notice is solely within the discretion of the Government.

Key dates

July 5, 2026Posted Date
July 10, 2026Proposals / Responses Due

AI search tags

neurotoxicity evaluation scientific consulting neural network development microelectrode array technology data analysis services

Frequently asked questions

NOTICE OF INTENT TO AWARD A SOLE SOURCE COMMERCIAL SIMPLIFIED ACQUISITION PROCEDURES (SAP) CONTRACT FOR DEVELOPMENT OF A HUMAN NEURAL NETWORK FORMATION NEW APPROACH METHOD FOR THE EVALUATION OF POTENTIAL DEVELOPMENTAL NEUROTOXICITY is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.